Robert W. Baird analyst Michael Polark maintained a Buy rating on Inspire Medical Systems (NYSE:INSP) on Thursday, setting a price target of $260, which is approximately 20.95% above the present share price of $214.96.
Polark expects Inspire Medical Systems to post earnings per share (EPS) of -$0.60 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Inspire Medical Systems, with an average price target of $250.17.
The analysts price targets range from a high of $265 to a low of $218.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $40.35 million and a net profit of -$15.69 million. The company's market cap is $5.86 billion.
According to TipRanks.com, Robert W. Baird analyst Michael Polark is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 14.8% and a 73.21% success rate.
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.